Published in Am J Respir Crit Care Med on September 17, 2010
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clin Infect Dis (2015) 1.43
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis (2012) 1.20
siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12
MicroRNA-221 modulates RSV replication in human bronchial epithelium by targeting NGF expression. PLoS One (2012) 1.02
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo. Adv Mater (2013) 1.01
Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis (2015) 0.96
The chemistry and biology of oligonucleotide conjugates. Acc Chem Res (2012) 0.95
Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection. PLoS One (2012) 0.94
Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res (2012) 0.93
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res (2012) 0.89
Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease. BMC Infect Dis (2011) 0.87
Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA. Mol Ther Nucleic Acids (2013) 0.86
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis (2014) 0.86
Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm (2014) 0.84
Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. Adv Virol (2013) 0.84
Clinical review: gene-based therapies for ALI/ARDS: where are we now? Crit Care (2011) 0.83
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses (2015) 0.83
An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology (2015) 0.82
Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Cancer Gene Ther (2014) 0.82
Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. Influenza Other Respir Viruses (2014) 0.82
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets (2012) 0.81
Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis. Antimicrob Agents Chemother (2012) 0.81
Lung transplantation: a treatment option in end-stage lung disease. Dtsch Arztebl Int (2014) 0.81
Technologies for controlled, local delivery of siRNA. J Control Release (2015) 0.80
Expression of non-structural-1A binding protein in lung epithelial cells is modulated by miRNA-548an on exposure to influenza A virus. Virology (2013) 0.80
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis. Mol Ther Nucleic Acids (2013) 0.79
Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother (2014) 0.79
Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol (2016) 0.78
RNA interference, RSV, and lung transplantation: a promising future for siRNA therapeutics. Am J Respir Crit Care Med (2011) 0.78
Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med (2014) 0.77
Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design. Immunology (2014) 0.77
siRNA Delivery from an Injectable Scaffold for Wound Therapy. Adv Wound Care (New Rochelle) (2013) 0.77
Assessing Modeled CO(2) Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants. ISRN Pediatr (2012) 0.75
How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood (2016) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems. Kona (2015) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems. Kona (2016) 0.75
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov (2006) 3.27
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ (2003) 3.03
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med (2012) 2.86
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell (2010) 2.64
Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 2.62
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood (2010) 2.49
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol (2007) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res (2010) 2.27
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2004) 2.23
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum (2003) 2.11
Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation (2004) 2.11
Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation (2006) 2.07
Successful lung transplantation for adolescents at a hospital for adults. Med J Aust (2007) 2.00
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis (2010) 1.98
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A (2010) 1.92
Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med (2004) 1.85
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet (2012) 1.75
Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol (2010) 1.67
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res (2009) 1.65
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis (2009) 1.64
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res (2006) 1.61
Mechanical ventilation after lung transplantation. An international survey of practices and preferences. Ann Am Thorac Soc (2014) 1.61
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg (2006) 1.59
An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology (2011) 1.58
Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation (2010) 1.53
Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm. J Heart Lung Transplant (2013) 1.53
C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation (2014) 1.49
Management of acute hypoxemia during flexible bronchoscopy with insertion of a nasopharyngeal tube in lung transplant recipients. Chest (2002) 1.45
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant (2005) 1.45
Epithelial and Erythrocyte Microvesicles From Bronchoalveolar Lavage Fluid Are Elevated and Associated With Outcome in Chronic Lung Allograft Dysfunction. Transplantation (2015) 1.41
Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis (2002) 1.37
Duplication and selection in the evolution of primate beta-defensin genes. Genome Biol (2003) 1.37
A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation (2010) 1.35
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.33
Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg (2006) 1.33
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther (2006) 1.30
Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant (2005) 1.25
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis (2012) 1.25
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol (2011) 1.23
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
A review of lung transplant donor acceptability criteria. J Heart Lung Transplant (2003) 1.16
Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev (2012) 1.15
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis (2005) 1.14
Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int (2013) 1.14
Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. Mol Imaging Biol (2006) 1.14
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum (2002) 1.12
Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol (2003) 1.12
Anticancer antibodies. Am J Clin Pathol (2003) 1.11
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis (2012) 1.10
Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol (2010) 1.09
A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant (2004) 1.09
Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle (2007) 1.09
Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J (2012) 1.09
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis (2004) 1.08
The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol Cancer Ther (2007) 1.08
The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation (2011) 1.07
Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation (2005) 1.05
A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis (2005) 1.05
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther (2009) 1.05
Renal function and survival in 200 patients undergoing ECMO therapy. Nephrol Dial Transplant (2012) 1.04
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci U S A (2002) 1.03
Liver as a target for oligonucleotide therapeutics. J Hepatol (2013) 1.02
Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation (2005) 1.02
Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation (2010) 1.02
Symptom experience after solid organ transplantation. J Psychosom Res (2008) 1.01
Symptom experience after lung transplantation: impact on quality of life and adherence. Clin Transplant (2007) 1.01
Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation (2012) 1.00
A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis (2007) 1.00
Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant (2002) 1.00
Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol (2011) 1.00
Impact of anastomotic airway complications after lung transplantation. Ann Thorac Surg (2007) 0.99
Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis (2003) 0.98
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther (2006) 0.98
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet (2005) 0.98
Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant (2008) 0.98
Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J Clin Virol (2002) 0.97
A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation (2007) 0.97
Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J Clin Microbiol (2008) 0.97
An international survey of cytomegalovirus management practices in lung transplantation. Transplantation (2010) 0.97
Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant (2002) 0.96
Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant (2007) 0.96
Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev (2005) 0.95
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation (2004) 0.95
Interventional lung assist: a new concept of protective ventilation in bridge to lung transplantation. ASAIO J (2008) 0.95